A phase II study of obinutuzumab in combination with ibrutinib for treatment of relapsed mantle cell lymphoma

Figures & data

Table 1. Baseline demographic and clinical-disease characteristics.

Characteristic	N = 10^1
Age at enrollment	72.0 (55.0, 81.1)
Sex
Female	1 (10.0%)
Male	9 (90.0%)
Race
White	10 (100.0%)
Ethnicity
Not Hispanic or Latino	10 (100.0%)
Disease status at enrollment
Stable disease	5 (50.0%)
Progressive	5 (50.0%)
MIPI Risk Class
Intermediate	3 (30.0%)
High	7 (70.0%)
Ki67 value (%)	65 (10, 90)
(Missing)	2
MIPI score	6.5 (4.0, 8.1)
ECOG at screening
0	1 (10.0%)
1	9 (90.0%)
Months between diagnosis and enrollment	21.5 (3.4, 116.9)

¹Statistics presented: Median (Minimum, Maximum); n (%).

Figure 1. Kaplan–Meier plot for progression-free survival in the efficacy-evaluable population.